CMB Stock News Of The Day 📰🗞️🗞️📈📉

“Moderna Beats Q1 Estimates, Sees Global Growth Despite Vaccine Transition” 🚨🚨🚨

Moderna reported stronger-than-expected first-quarter 2026 results, beating Wall Street estimates and reaffirming its full-year outlook as the company continues its shift beyond its COVID-era peak.

For Q1, Moderna posted an adjusted loss of $3.40 per share, outperforming analyst expectations for a $4.45 loss. Revenue came in at $352 million, well above the $236 million forecast. Roughly 80% of that revenue was generated outside the United States, underscoring the company’s growing international footprint.

Despite declining demand for its COVID-19 vaccine—once its primary revenue driver—Moderna maintained its full-year guidance, still expecting approximately 10% revenue growth in 2026. Analysts currently project around $2 billion in annual sales, representing roughly 5% growth.

A key driver of optimism is regulatory progress in Europe, where the European Commission approved Moderna’s combination flu and COVID-19 vaccine for adults aged 50 and older. The company sees this as a potential catalyst for renewed growth.

However, expansion in the U.S. remains more challenging. The Food and Drug Administration has been slower to approve new products, though it indicated in February it would reconsider Moderna’s standalone flu vaccine.

As the company pivots away from pandemic-driven revenue, its international markets are increasingly becoming the backbone of its business strategy.